论文信息 - After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. - 字舞流文

After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.

C. Wanner | T. Benzing | F. Artunc | N. Heyne | C. Fitzner | B. Banas | K. Budde | F. Eitner | T. Rauen | J. Floege | U. Panzer | C. Sommerer | M. Zeier | H. Haller | G. Wolf | M. Fischereder | R. Hilgers | O. Witzke | T. Mettang | P. Mertens | M. Moeller | R. Schindler | O. Gross | Anna Bertram | H. Weihprecht | T. Metzger | S. Elitok | B. Hohenstein | K. Hilgers | H. Reichel | C. Hugo | U. Kuhlmann | U. Frei | F. Grundmann | M. Stefanidou | T. Rath | H. Pavenstädt | M. Busch | V. Vielhauer | U. Göttmann | U. Benck | H. Peters | C. Erley | M. Bieringer | K. Schlieps | S. Canaan-kühl | S. Wied | C. Palm | Britta Otte | J. Mann | Frans Zandvoort | S. Ziefle | Stefan Westphalen | O. Sarkar | Alexander Boeger | Volker Vielhauer | JohannesF. E. Mann

[1] B. Julian,et al. IgA nephropathy. , 2020, The New England journal of medicine.

[2] Keiichi Matsuzaki,et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. , 2019, JAMA internal medicine.

[3] V. Perkovic,et al. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[4] C. Fitzner,et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores) , 2018, BMC Nephrology.

[5] M. Rudnicki,et al. Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss. , 2018, Journal of the American Society of Nephrology : JASN.

[6] J. Barratt,et al. Treatment of IgA Nephropathy: Evolution Over Half a Century. , 2018, Seminars in nephrology.

[7] R. Coppo. IgA Nephropathy: A European Perspective in the Corticosteroid Treatment , 2018, Kidney Diseases.

[8] C. Fitzner,et al. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[9] David W. Johnson,et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial , 2017, JAMA.

[10] J. Feehally,et al. An update on the treatment of IgA nephropathy , 2017, Current opinion in nephrology and hypertension.

[11] F. Locatelli,et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial , 2017, The Lancet.

[12] F. Schena,et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. , 2015, The New England journal of medicine.

[13] A. Cheung,et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14] F. Locatelli,et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[15] S. Tang,et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. , 2010, Kidney international.

[16] F. Schena,et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17] B. Kasiske,et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18] F. Eitner,et al. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. , 2008, Journal of nephrology.

[19] J. Scholey,et al. Remission of proteinuria improves prognosis in IgA nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.

[20] L. Peruzzi,et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. , 2007, Journal of the American Society of Nephrology : JASN.

[21] E. Morales,et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. , 2003, Journal of the American Society of Nephrology : JASN.

[22] F. Locatelli,et al. Corticosteroids in IgA nephropathy: a randomised controlled trial , 1999, The Lancet.

[23] R. Coppo. Corticosteroids in IgA Nephropathy: Lessons from Recent Studies. , 2017, Journal of the American Society of Nephrology : JASN.

[24] C. Fitzner,et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. , 2015, The New England journal of medicine.

[25] B. Kasiske,et al. KDIGO Clinical Practice Guideline for Glomerulonephritis , 2012 .

[26] Ajay K. Singh,et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27] Claudio Pozzi,et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. , 2004, Journal of the American Society of Nephrology : JASN.

[28] I. Roberts,et al. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. , 2002, Journal of the American Society of Nephrology : JASN.